#### AMENDMENTS TO THE CLAIMS

The following listing of claims will replace all prior versions, and listings, of claims in the application.

# Listing of claims:

### Claims 1 to 8 (canceled).

Claim 9 (original). A compound of Formula IV

$$\mathbb{R}^{7}$$
 $(CH_2)_n$ 
 $O$ 
 $(CH_2)_n$ 
 $(CH_2$ 

or a pharmaceutically acceptable salt thereof,

wherein Each n independently is an integer of from 0 to 6;

 $R^2$  is hydrogen, halo, hydroxy,  $C_1$ - $C_6$  alkyl,  $C_1$ - $C_6$  alkoxy,  $C_2$ - $C_6$  alkenyl,

 $C_2$ - $C_6$  alkynyl,  $NO_2$ ,  $NR^4R^5$ , CN, or  $CF_3$ ; and  $R^6$ ,  $R^7$ ,  $R^8$ , and  $R^9$ 

independently are hydrogen, halo, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, nitro, or NH<sub>2</sub>;

 ${
m R}^4$  and  ${
m R}^5$  independently are H,  ${
m C}_1$ - ${
m C}_6$  alkyl,  ${
m C}_2$ - ${
m C}_6$  alkenyl,  ${
m C}_2$ - ${
m C}_6$  alkynyl,

 $(CH_2)_n$  aryl,  $(CH_2)_n$  cycloalkyl,  $(CH_2)_n$  heteroaryl, or  $R^4$  and  $R^5$  when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing a heteroatom selected from O, S, or NH, and optionally substituted or unsubstituted.

## Claim 10 (canceled).

Claim 11 (original). A compound selected from:

- Pyrimidine-4,6-dicarboxylic acid, (4-chloro-benzylamide), [(1,3-benzodioxol-5-ylmethyl)-amide];
- Pyrimidine-4,6-dicarboxylic acid, (4-carboxy-benzylamide), [(1,3-benzodioxol-5-ylmethyl)-amide];
- Pyrimidine-4,6-dicarboxylic acid, (4-carboxy-benzylamide), (4-methoxy-benzylamide);
- Pyrimidine-4,6-dicarboxylic acid, (4-carboxy-benzylamide), (3-methoxy-benzylamide);
- Pyrimidine-4,6-dicarboxylic acid, (4-carbomethoxy-benzylamide), (3-methoxy-benzylamide);
- Pyrimidine-4,6-dicarboxylic acid, (4-carboxy-benzylamide), (3-pyridylmethylamide);
- Pyrimidine-4,6-dicarboxylic acid, (4-carboxy-benzylamide), (3-thiophenemethylamide);
- Pyrimidine-4,6-dicarboxylic acid, (2,1,3-benzothiadiazol-5-ylmethyl) amide, [(1,3-benzodioxol-5-ylmethyl)-amide];
- Pyrimidine-4,6-dicarboxylic acid, (2,1,3-benzooxadiazol-5-ylmethyl) amide, [(1,3-benzodioxol-5-ylmethyl)-amide];
- Pyrimidine-4,6-dicarboxylic acid, (2,1,3-benzothiadiazol-5-ylmethyl) amide, (4-methoxy-benzylamide);
- Pyrimidine-4,6-dicarboxylic acid, (2,1,3-benzothiadiazol-5-ylmethyl) amide, (3-methoxy-benzylamide);
- Pyrimidine-4,6-dicarboxylic acid bis-(1,3-benzodioxol-5-ylmethyl) ester;

Pyrimidine-4,6-dicarboxylic acid, bis-(4-chloro-benzylamide);

Pyrimidine-4,6-dicarboxylic acid, bis-[(1,3-benzodioxol-5-ylmethyl)-amide];

Pyrimidine-4,6-dicarboxylic acid, bis-(4-methoxy-benzylamide);

Pyrimidine-4,6-dicarboxylic acid, bis-(3-methoxy-benzylamide);

Pyrimidine-4,6-dicarboxylic acid, bis-(4-carboxy-benzylamide); and

Pyrimidine-4,6-dicarboxylic acid, bis-(4-carbomethoxy-benzylamide).

### Claims 12 to 14 (canceled).

Claim 15 (withdrawn). The pharmaceutical composition according to

Claim 12, comprising an MMP-13 inhibiting amount of a compound of Formula

IV, or a pharmaceutically acceptable salt thereof, A pharmaceutical composition,

comprising an MMP-13 inhibiting amount of a compound of Claim 9, or a

pharmaceutically acceptable salt thereof, together with a pharmaceutically

acceptable carrier, diluent, or excipient.

## Claims 16 to 21 (canceled).

- Claim 22 (currently amended). A method for treating inflammation, comprising administering to a patient in need of treatment an effective amount of a compound of Formula I Claim 9, or a pharmaceutically acceptable salt thereof.
- Claim 23 (currently amended). A method for treating osteoarthritis, comprising administering to a patient in need of treatment an effective amount of a compound of Formula I Claim 9, or a pharmaceutically acceptable salt thereof.
- Claim 24 (currently amended). A method for treating rheumatoid arthritis, comprising administering to a patient in need of treatment an effective amount of a compound of Formula I Claim 9, or a pharmaceutically acceptable salt thereof.

Claim 25 (canceled).